Schulte-Hermann R, Parzefall W
Cancer Res. 1981 Oct;41(10):4140-6.
alpha-Hexachlorocyclohexane (alpha-HCH) was administered p.o. to female Wistar rats for periods of up to 33 months; doses were 20 mg/kg/day, 200 mg/kg every second week, or 420 mg/kg every third week. Increases of liver size, DNA, RNA, and protein (by 50 to 100%) and of drug-metabolizing enzyme activities (up to 300%) observed previously after single doses of alpha-HCH were found to persist after approximately one-third, 1, and 2 years of treatment. At 1 and 2 years, DNA synthesis was measured by [3H]thymidine uptake and was no higher than in controls. All changes regressed upon withdrawal of alpha-HCH after 1 year of treatment. These findings provide no evidence to suggest a protracted development of toxicity or of growth autonomy in the majority of liver cells. Foci of altered cells, neoplastic nodules, and in 2 animals hepatocellular carcinoma were detected histologically in the livers of 24 of 34 treated rats. In livers of 10 of 22 untreated control rats, foci of altered cells developed "spontaneously" between 12 and 34.5 months. If neoplastic lesions were induced by a single dose of diethylnitrosamine, 75 or 150 mg/kg, subsequent treatment with alpha-HCH led to the appearance of hepatocellular carcinoma with 7 months. Altogether, hepatocellular carcinoma within 7 months. Altogether, hepatocellular carcinomas were found in 18 of 21 rats treated with both agents but in only 3 of 26 animals treated with diethylnitrosamine alone. The results show that determination of tumor numbers alone in a long-term animal experiment does not allow one to decide whether alpha-HCH (and similar "xenobiotic inducers") is an initiating carcinogen or merely promotes tumorigenesis from "spontaneous" lesions. Our findings support the latter possibility by the failure to detect evidence suggesting initiating potential of alpha-HCH, by the enhanced mitotic response to alpha-HCH, by the enhanced mitotic response to alpha-HCH in foci of altered cells as reported elsewhere, and by the observation of a permanent stimulatory action on liver growth during prolonged exposure to alpha-HCH.
将α-六氯环己烷(α-HCH)经口给予雌性Wistar大鼠,给药时间长达33个月;剂量分别为20毫克/千克/天、每两周200毫克/千克或每三周420毫克/千克。先前单次给予α-HCH后观察到的肝脏大小、DNA、RNA和蛋白质增加(50%至100%)以及药物代谢酶活性增加(高达300%),在治疗约三分之一年、1年和2年后仍持续存在。在1年和2年时,通过[3H]胸苷摄取测量DNA合成,其值不高于对照组。在治疗1年后停用α-HCH后,所有变化均消退。这些发现没有提供证据表明大多数肝细胞中存在毒性的长期发展或生长自主性。在34只接受治疗的大鼠中的24只肝脏中,组织学检测到细胞改变灶、肿瘤结节,在2只动物中检测到肝细胞癌。在22只未治疗的对照大鼠中的10只肝脏中,细胞改变灶在12至34.5个月之间“自发”出现。如果用单剂量75或150毫克/千克的二乙基亚硝胺诱导肿瘤病变,随后用α-HCH治疗会在7个月内导致肝细胞癌的出现。总共,在7个月内出现肝细胞癌。总共,在同时接受两种药物治疗的21只大鼠中的18只发现了肝细胞癌,但在仅接受二乙基亚硝胺治疗的26只动物中只有3只发现了肝细胞癌。结果表明,在长期动物实验中仅确定肿瘤数量,无法让人判断α-HCH(以及类似的“外源性诱导剂”)是引发致癌物还是仅仅从“自发”病变促进肿瘤发生。我们的发现支持后一种可能性,这是由于未检测到表明α-HCH具有引发潜力的证据、对α-HCH的有丝分裂反应增强、如其他地方所报道的在细胞改变灶中对α-HCH的有丝分裂反应增强,以及观察到在长期暴露于α-HCH期间对肝脏生长有永久性刺激作用。